OTCMKTS:SPHRY - Starpharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.60
▲ +0.15 (1.20%)

This chart shows the closing price for SPHRY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Starpharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPHRY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPHRY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Starpharma in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.60.

This chart shows the closing price for SPHRY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Starpharma. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/16/2019MacquarieInitiated CoverageOutperform
(Data available from 6/21/2016 forward)
Starpharma logo
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Read More

Today's Range

Now: $12.60
Low: $12.60
High: $12.80

50 Day Range

MA: $13.31
Low: $12.39
High: $15.00

52 Week Range

Now: $12.60
Low: $7.21
High: $19.87

Volume

900 shs

Average Volume

3,070 shs

Market Capitalization

$511.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Starpharma?

The following sell-side analysts have issued research reports on Starpharma in the last year:
View the latest analyst ratings for SPHRY.

What is the current price target for Starpharma?

0 Wall Street analysts have set twelve-month price targets for Starpharma in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Starpharma in the next year.
View the latest price targets for SPHRY.

What is the current consensus analyst rating for Starpharma?

Starpharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SPHRY.

What other companies compete with Starpharma?

How do I contact Starpharma's investor relations team?

Starpharma's physical mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The company's listed phone number is 61-3-8532-2700 and its investor relations email address is [email protected] The official website for Starpharma is www.starpharma.com.